Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ligue contre le cancer, France | OTHER |
Not provided
Not provided
Not provided
Not provided
The present study proposes a new organization of the Day Hospital unit with several possible pathways defined by PRO.
The organization realies on a platform composed of nurses supervised by an IPA and a doctor one day before a treatment in the day hospitalization unit admission, results of PROs collectyed through the CEM@santé application (a French health care application) are reviewed by nurses from the platform and chemotherapy delivery is confirmed.
The study is planed in 2 steps.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| front phase | Other | The current circuit remains unchanged (medical or nursing validation to confirm chemotherapy administration). Patient satisfaction is collected at each visit to the day hospital unit for chemotherapy. |
|
| Post Phase | Other | A short circuit is set up. If no contraindications are identified by the plateform with the remote PRO collection, patients will undergo chemotherapy directly the next day (without any medical validation). Patient satisfaction is also collected at each visit to the day hospital unit for chemotherapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Standard follow up | Other | Patients enrolled into front phase will be followed in a standard way without any additional procedure except satisfaction questionnaire |
|
| Measure | Description | Time Frame |
|---|---|---|
| Duration of stay in day hospital unit | Assess the impact on the duration of stay of an anticipated personalization of the stay in HDJ based on a platform of analysis of the PROs collected the day before and the implementation of a short circuit | Immediately after the chemotherapy |
| Measure | Description | Time Frame |
|---|---|---|
| patient satisfaction | Assessed by EORTC OUT-PATSAT7 ( patient satisfaction with cancer care core questionnaire). satisfaction score between 0 (no satisfaction) and 100 (high satisfaction) | Immediately after the chemotherapy |
| Caregiver satisfaction |
Not provided
Inclusion Criteria:
Note1: may be used in combination with tyrosine kinase inhibitors (TKIs) Note 2 :may be used in combination with bevacizumab, cetuximab or panitumumab
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre de lutte contre le cancer Eugène Marquis | Rennes | 35042 | France |
Not provided
| ID | Term |
|---|---|
| D010549 | Personal Satisfaction |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
1st stage: the current circuit remains unchanged (with sytematic medical or nursing validation to confirm chemotherapy administration).
Not provided
Not provided
Not provided
Not provided
| short circuit | Other | Patients included in the post phase will have to complete the "cem@santé" application. If no contraindications are identified by the plateform with the remote PRO collection, patients will undergo chemotherapy directly the next day (without any medical validation). |
|
Assessed by self questionnaire
| Month3;Month6 |
| Health related patient quality of life | Assessed by EQ5D-5L (EuroQuol Five Dimension - Five Level Health Survey questionnaire) The scale has five subcomponents with scores from 1 (best) to 5 (worst) | Immediately after the chemotherapy |